Skip to content

Author

A. Hageen

We have 5 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

Abstract 17110: Baxdrostat in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Introduction: Resistant hypertension remains difficult to control and is associated with increased cardiovascular and renal risk. Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a potential therapeutic option for adults with uncontrolled or resistant hypertension. We evaluated the efficacy and...

A. Gadelmawla, A. Hageen, R. Rateb et al. · 0 citations
Review Open access Sep 2026

Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

This network meta‐analysis addresses the limited dose‐specific comparative evidence by evaluating different doses of tirzepatide (TZP) versus dulaglutide (DULA) for glycemic control, weight loss, and safety in type 2 diabetes mellitus (T2DM).

A. Hageen, A. Gadelmawla, A. O. Saleh et al. · 0 citations
Review Open access Aug 2026

“Left Atrial Appendage Closure Versus Medical Therapy in Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials”

LAAC provides similar overall efficacy and safety compared with medical therapy for stroke prevention in AF but should currently remain reserved for selected patients rather than replacing oral anticoagulation broadly, indicating current evidence remains underpowered and additional randomized trials are needed.

A. AL-Janabi, A. Al-shammari, A. Hageen et al. · 0 citations
Review Aug 2026

Efficacy and Safety of Baxdrostat for Patients With Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis.

Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.

A. Gadelmawla, A. Hageen, R. Rateb et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.